Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy
Condition: Leprosy Interventions: Drug: BE-PEP Bedaquiline; Drug: SDR-PEP Rifampicin; Drug: BE-PEP Rifampicin Sponsor: Institute of Tropical Medicine, Belgium Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 28, 2022 Category: Research Source Type: clinical trials
Comparison of 8 weeks standard treatment (rifampicin plus clarithromycin) vs. 4 weeks standard plus amoxicillin/clavulanate treatment [RC8 vs. RCA4] to shorten Buruli ulcer disease therapy (the BLMs4BU trial): study protocol for a randomized controlled multi-centre trial in Benin
DiscussionIf successful, this study will create a new paradigm for BU treatment, which could inform World Health Organization policy and practice. A shortened, highly effective, all-oral regimen will improve care of BU patients and will lead to a decrease in hospitalization-related expenses and indirect and social costs and improve treatment adherence. This trial may also provide information on treatment shortening strategies for other mycobacterial infections (tuberculosis, leprosy, or non-tuberculous mycobacteria infections).Trial registrationClinicalTrials.govNCT05169554. Registered on 27 December 2021. (Source: Trials)
Source: Trials - July 8, 2022 Category: Research Source Type: clinical trials
